Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells
Matthew Stuible, Christian Gervais, Simon Lord‐Dufour, et al.
Journal of Biotechnology (2020) Vol. 326, pp. 21-27
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

A scalable serology solution for profiling humoral immune responses to SARS‐CoV‐2 infection and vaccination
Karen Colwill, Yannick Galipeau, Matthew Stuible, et al.
Clinical & Translational Immunology (2022) Vol. 11, Iss. 3
Open Access | Times Cited: 105
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Jun Liu, Patrick Budylowski, Reuben Samson, et al.
Science Advances (2022) Vol. 8, Iss. 3
Open Access | Times Cited: 41
A CHO stable pool production platform for rapid clinical development of trimeric SARS‐CoV‐2 spike subunit vaccine antigens
Simon Joubert, Matthew Stuible, Simon Lord‐Dufour, et al.
Biotechnology and Bioengineering (2023) Vol. 120, Iss. 7, pp. 1746-1761
Open Access | Times Cited: 23
Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individuals
Abdelhadi Djaïleb, Maryam Hojjat Jodaylami, Julien Coutu, et al.
The Analyst (2021) Vol. 146, Iss. 15, pp. 4905-4917
Open Access | Times Cited: 41
Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant
Bassel Akache, Tyler M. Renner, Anh Tran, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 41
Investigating the metabolic load of monoclonal antibody production conveyed to an inducible CHO cell line using a Transfer-Rate Online Monitoring system
Sebastian‐Juan Reyes, Lucas Lemire, Yves Durocher, et al.
Journal of Biotechnology (2025)
Open Access
SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.
Melanie L. Carroll, Heather Fox, Anh Tran, et al.
Vaccine (2025) Vol. 54, pp. 126988-126988
Open Access
Production of trimeric SARS‐CoV‐2 spike protein by CHO cells for serological COVID‐19 testing
Yusuf B. Johari, Stephen Jaffe, Joseph M. Scarrott, et al.
Biotechnology and Bioengineering (2020) Vol. 118, Iss. 2, pp. 1013-1021
Open Access | Times Cited: 43
Production of high‐quality SARS‐CoV‐2 antigens: Impact of bioprocess and storage on glycosylation, biophysical attributes, and ELISA serologic tests performance
Rute Castro, Lígia S. Nobre, Rute P. Eleutério, et al.
Biotechnology and Bioengineering (2021) Vol. 118, Iss. 6, pp. 2202-2219
Open Access | Times Cited: 39
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants
Linda van Oosten, Jort J. Altenburg, Cyrielle Fougeroux, et al.
mBio (2021) Vol. 12, Iss. 5
Open Access | Times Cited: 32
Upstream cell culture process characterization and in-process control strategy development at pandemic speed
Jianlin Xu, Jianfa Ou, Kyle P. McHugh, et al.
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 24
Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models
Martín A. Rossotti, Henk van Faassen, Anh Tran, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 21
Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern
Bassel Akache, Tyler M. Renner, Matthew Stuible, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 20
Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
Maryam Hojjat Jodaylami, Abdelhadi Djaïleb, Pierre Ricard, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 25
Structure-based dual affinity optimization of a SARS-CoV-1/2 cross-reactive single-domain antibody
Traian Sulea, Jason Baardsnes, Matthew Stuible, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0266250-e0266250
Open Access | Times Cited: 17
Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern
Tyler M. Renner, Bassel Akache, Matthew Stuible, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Expression, purification and characterization of SARS-CoV-2 spike RBD in ExpiCHO cells
Matteo De March, Michela Terdoslavich, Sulena Polez, et al.
Protein Expression and Purification (2022) Vol. 194, pp. 106071-106071
Open Access | Times Cited: 15
Insect Cells for High-Yield Production of SARS-CoV-2 Spike Protein: Building a Virosome-Based COVID-19 Vaccine Candidate
Bárbara Fernandes, Rute Castro, Farien Bhoelan, et al.
Pharmaceutics (2022) Vol. 14, Iss. 4, pp. 854-854
Open Access | Times Cited: 15
Longitudinal Study on Seroprevalence and Immune Response to SARS-CoV-2 in a Population of Food and Retail Workers Through Transformation of ELISA Datasets
Abdelhadi Djaïleb, Megan-Faye Parker, Étienne Lavallée, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Scalable bioprocess for high-yield production of SARS-CoV-2 trimeric spike protein-based immunogen (IMT-CVAX) using suspension CHO cells
Sneha Singh, B. Vikram Kumar, Jitender, et al.
Process Biochemistry (2024) Vol. 147, pp. 332-346
Closed Access | Times Cited: 2
An unconventional strategy for purifying recombinant SARS-CoV-2 spike protein
Mrunal Ingawale, Mohammad Riaz, Yves Durocher, et al.
Journal of Chromatography B (2024) Vol. 1247, pp. 124328-124328
Open Access | Times Cited: 2
Longitudinal determination of seroprevalence and immune response to SARS-CoV-2 in a population of food and retail workers through decentralized testing and transformation of ELISA datasets
Abdelhadi Djaïleb, Megan-Faye Parker, Étienne Lavallée, et al.
PLoS ONE (2024) Vol. 19, Iss. 12, pp. e0314499-e0314499
Open Access | Times Cited: 2
Recombinant Protein Expression and Purification of N, S1, and RBD of SARS-CoV-2 from Mammalian Cells and Their Potential Applications
Julio García‐Cordero, Noe Juvenal Mendoza-Ramírez, David Andrés Fernández-Benavides, et al.
Diagnostics (2021) Vol. 11, Iss. 10, pp. 1808-1808
Open Access | Times Cited: 18
Impact of the temperature on the interactions between common variants of the SARS-CoV-2 receptor binding domain and the human ACE2
Catherine Forest‐Nault, Izel Koyuturk, Jimmy Gaudreault, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 12
Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells
Sergio P. Alpuche-Lazcano, Matthew Stuible, Bassel Akache, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top